Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05).
In February 1996 the Trans-Tasman Radiation Oncology Group (TROG) initiated a two-arm, multicentre, prospective randomized trial on radiotherapy for neuropathic pain due to bone metastases (TROG 96.05). This trial compares the response to a single 8-Gy fraction with 20 Gy in five fractions. The accrual target is 270 patients. In order to evaluate compliance with eligibility criteria after approximately 1 year of accrual, an independent audit of the first 42 randomized patients was commissioned. This found that only one of these patients did not have genuine neuropathic pain, but that this patient and seven others (19%) had infringements of other eligibility/exclusion criteria for the trial. Accordingly it was decided to continue the full audit up to 90 patients. This detected no further patients without genuine neuropathic pain, and found only one other eligibility infringement (1/48; 2%). It is concluded that this quality assurance (QA) measure undertaken early in the trial led to significantly improved clinician awareness of, and compliance with, eligibility/exclusion criteria. It also enabled an accurate comparison of outcome data for all randomized versus all eligible patients at the time of the preplanned first interim analysis at 90 patients. In view of the excellent compliance demonstrated in the second audit, a one-in-five sampling is proposed for future audits from centres that have already accrued at least five consecutive eligible patients. This is consistent with TROG QA guidelines now operational.
Roos
D E
DE
Royal Adelaide Hospital, South Australia. droos@mail.rah.sa.gov.au
Davis
S R
SR
O'Brien
P C
PC
Hoskin
P J
PJ
Spry
N A
NA
Burmeister
B H
BH
Turner
S L
SL
Bernshaw
D M
DM
D001859:Bone Neoplasms / Q000150:complications* / Q000556:secondary; D006801:Humans; D008485:Medical Audit; D015337:Multicenter Studies as Topic / Q000379:methods / Q000592:standards; D010146:Pain / Q000209:etiology / Q000503:physiopathology / Q000532:radiotherapy*; D010349:Patient Compliance; D018579:Patient Selection; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000503:physiopathology / Q000532:radiotherapy*; D011786:Quality Control; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards*; D015203:Reproducibility of Results